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Abstract
In a number of literature reports iron oxide nanoparticles have been investigated for use in
imaging atherosclerotic plaques and found to accumulate in plaques via uptake by macrophages,
which are critical in the process of atheroma initiation, propagation, and rupture. However, the
uptake of these agents is nonspecific, thus the labeling efficiency for plaques in vivo is not ideal.
We have developed targeted agents to improve the efficiency for labeling macrophage-laden
plaques. These probes are based on iron oxide nanoparticles coated with dextran sulfate, a ligand
of macrophage scavenger receptor type A (SR-A). We have sulfated dextran-coated iron oxide
nanoparticles (DIO) with sulfur trioxide, thereby targeting our nanoparticle imaging agents to SR-
A. The sulfated DIO (SDIO) remained mono-dispersed and had an average hydrodynamic
diameter of 62 nm, an r1 relaxivity of 18.1 mM−1s−1, and an r2 relaxivity of 95.8 mM−1s−1 (37
°C, 1.4 T). Cell studies confirmed that these nanoparticles were nontoxic and specifically targeted
to macrophages. In vivo MRI after intravenous injection of the contrast agent into an
atherosclerotic mouse injury model showed substantial signal loss on the injured carotid at 4 and
24 hours post-injection of SDIO. No discernable signal decrease was seen at the control carotid
and only mild signal loss was observed for the injured carotid post-injection of non-sulfated DIO,
indicating preferential uptake of the SDIO particles at the site of atherosclerotic plaque. These
results indicate that SDIO can facilitate MRI detection and diagnosis of vulnerable plaques in
atherosclerosis.
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1. Introduction
Cardiovascular disease (CVD) is the leading cause of death in the western world and its
prevalence is expected to increase further during the next 3 decades.[1] Increasing evidence
indicates that it is atherosclerotic plaque rupture rather than severity of vessel occlusion that
leads to major adverse events, such as stroke and myocardial infarction.[2–3] Early
detection of unstable plaques would be of great value to guide treatment decisions, with the
aim to decrease morbidity/mortality in affected patients. There is an intense focus in the
field to identify specific biomarkers that indicate a plaque's risk for rupture and develop
noninvasive methods to detect those markers.[1, 4–5] Magnetic resonance imaging (MRI)
has played a prominent role in anatomical and functional examinations of the major vessels;
however, without signal enhancement, the technique lacks sufficient sensitivity to directly
detect and identify biomarkers of interest.[6–7]
Recent advances in the development of MRI contrast agents (CAs), which specifically target
relevant biomarkers and enhance images to generate sufficient contrast in tissues and organs
of interest, allow MRI to visualize molecules and molecular events occurring at a cellular
level.[6, 8] However, the amount of biomarkers in the cardiovascular system is usually
expressed in the low nanomolar range (≤ 10−9 mol/g of tissue), which is below the detection
sensitivity of routinely used gadolinium chelates (10−7 mol/g of tissue). Particle-based
technologies provide an effective method to concentrate signal-generating materials into a
relatively small entity, which can greatly improve their detectability (10−10 – 10−11 mol/g of
tissue) in vivo.[7, 9–10] Moreover, the particle CAs have a large surface areas, allowing
them to display more targeting ligands, further enriching the CAs at the region of interest
(ROI).
Non-toxic and biocompatible iron oxide nanoparticles (IO NPs) have been widely used as
MRI CAs in the clinic.[11] IO NPs, however, are generally non-specific; they show a
differential distribution in the body based primarily on relative tissue permeability. We are
interested in the development of IO NP CAs that target biomarkers of atherosclerotic
plaques. In the search for markers to identify high-risk plaque, macrophages have been
found to correlate with plaque stability --- plaques with high macrophage content tend to be
more unstable, and the distribution pattern for the macrophages can be indicative of degree
of stability.[12–13] IO NPs have been used for MRI detection of plaques in pre-clinical
experiments using different animal models of atherosclerosis, and the results showed that
these particles accumulate in plaque macrophages.[14] However, the uptake of IO NPs by
macrophages is nonspecific through phagocytosis. This is an inefficient process that
provides relatively weak contrast between the plaque and surrounding tissues.[15]
We have previously developed CAs based on the scavenger receptor type A (SR-A)
targeting ligands maleylated BSA and dextran sulfate.[16–18] SR-A is highly expressed on
activated macrophages and not found on normal vessel walls.[19] These probes labeled
atherosclerotic plaques with improved efficiency over non-targeted probes. However, it was
difficult to obtain mono-dispersed IO NPs by synthesizing them using either dextran sulfate,
or a combination of dextran sulfate and dextran, as a starting materials to form the coating.
[20] In this work, we introduce a new synthetic method in which we coated IO NPs with
dextran (DIO), then sulfated the dextran coating of the particles to make dextran sulfate
coated IO NPs (SDIO). The ability of SDIO to target macrophages in vitro and to detect and
access macrophages in atherosclerotic plaque in vivo was evaluated by MRI.
Tu et al. Page 2
Biomaterials. Author manuscript; available in PMC 2012 October 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
2. Materials and methods
2.1. Materials
Materials were obtained from commercial suppliers and used directly, unless otherwise
noted. Dextran (from leuconostoc, average mol. wt. 9,000–11,000) and ferric chloride
hexahydrate (FeCl3·6H2O, Fw 270.29 g/mol) were purchased from Sigma-Aldrich. Ferrous
chloride tetrahydrate (FeCl2·4H2O, Fw 198.81 g/mol) and dextran sulfate (sodium salt,
prepared from dextran from leuconostoc SSP., average mol. wt. 5,000) were acquired from
Fluka. Ammonium hydroxide (28–30%), sodium bicarbonate and sodium hydroxide were
provided by Fisher Scientific. Sulfur trioxide pyridine complex, sulfur trioxide DMF
complex and 2-methyl-2-butene (2M2B) were purchased from Acros. Anhydrous
formamide was purchased from MP, Biomedicals, LLC. Spectra/por® dialysis membrane
(mol. wt. cut-off 50,000) was purchased from Spectrum Laboratories, Inc. P388D1 cells and
RPMI-1640 medium were obtained from American Type Culture Collection (ATCC). Fetal
bovine serum (FBS), L-glutamine, PBS (1X) and C12 – Resazurin were provided by
GIBCO. Lipoprotein deficient bovine serum (LPDS) was obtained from Biomedical
Technologies, Inc. (Stoughton, MA). Water was purified using a Millipore Milli-Q
Synthesis purifier (18.0 MΩ cm, Barnstead).
2.2. Synthesis of dextran sulfate coated iron oxide nanoparticles
Dextran coated iron oxide nanoparticles (DIO) were synthesized as previously reported.[20]
The DIO (200 mg) was dissolved in 10 mL of dry formamide. After complete dissolution, 2-
methyl-2-butene (2M2B) (1.6 mL, 15 mmol) was slowly added to the flask under argon
atmosphere and magnetic stirring. A SO3–pyridine complex (0.32 g, 2 mmol) was rapidly
added, and the reaction mixture was stirred at 30 °C under argon atmosphere for 2 h. The
reaction was quenched by slowly pouring it into 7 mL of saturated sodium bicarbonate
solution. After the final product was concentrated, the residue was dissolved in water and
was dialyzed against deionized water in a dialysis bag with molecular weight (MW) cut-off
of 50,000 Dalton for 72 h (8–10 changes of water). The solution was lyophilized to give a
brown solid.
2.3. Characterization of SDIO
The iron oxide core size of SDIO and DIO were measured by transmission electron
microscopy (TEM) on a Philips CM-12, operating at 80 kV. The average hydrodynamic
particle size and size distribution of SDIO and DIO were measured using dynamic light
scattering (DLS) with a Nanotrac 150 particle size analyzer (Microtrac, Inc.,
Montgomeryville, PA). The zeta potential (ζ) values of SDIO and DIO were measured by
determining the electrophoretic mobility using a NICOMP™ 380 ZLS device (Particle
Sizing Systems, Inc., Santa Barbara, CA, USA) in deionized water at room temperature.
Elemental analysis was performed by Columbia Analytical Services of Tucson, Arizona.
FT-IR spectra were collected on a Shimadzu IR Prestige 21 spectrophotometer.
Longitudinal (T1) and transverse (T2) relaxation times were measured at 60 MHz (1.4 T) and
37 °C on a Bruker Minispec mq60 (Bruker, Billerica, MA). Three stock solutions of SDIO
were prepared by dissolving appropriate amounts of particles in pH 7.0 deionized water. The
concentration of iron was determined by ICP-MS. The stock solutions were diluted to give
three series of aqueous solutions with decreasing iron concentration (0.3 mL each). All
solutions were prepared by weight. Iron concentrations were calculated based on the
concentration of the stock solution and appropriate dilution factors. T1 values were measured
using an inversion recovery sequence with 10–15 data points and T2 values were measured
using a Carr–Purcell–Meiboom–Gill (CPMG) sequence with τ = 1 ms, and 200 data points.
Each solution was incubated at 37 °C for 10 min before measurement. The longitudinal (r1)
Tu et al. Page 3
Biomaterials. Author manuscript; available in PMC 2012 October 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
and transverse (r2) relaxivity were determined as the slope of the line for plots of 1/T1 or 1/
T2, respectively, against increasing iron concentration with a correlation coefficient greater
than 0.99.[21] The relaxivity of DIO was measured by the same procedure. The T1 and T2
relaxation times of cell lysates containing SDIO or DIO were also measured with the
method described above.
2.4. Cell experiments
2.4.1. Cell culture—The P388D1 cells were maintained in tissue culture flasks (75 cm2)
in media (RPMI-1640 with 1% L-glutamine and 10% fetal bovine serum (FBS)) at 37 °C in
a humidified environment of 5% CO2 atmosphere. When the cells reached 80–90%
confluence, the medium was removed. The cells were scraped down with a rubber
policeman and used for either sub-culture or in vitro cell studies. All experiments were
performed on cells that were passaged an equal number of times.
2.4.2. In vitro cellular uptake of SDIO and DIO—The P388D1 cells were plated to 60
mm diameter tissue culture dishes at 1 × 106 cells/mL of RPMI-1640 with 1% L-glutamine
and 10% lipoprotein deficient bovine serum (LPDS) (2 mL per dish). The cells were
maintained in media at 37 °C in a humidified environment of 5% CO2 atmosphere overnight
which allowed cells to adhere to the bottom of dishes.
Three stock solutions of SDIO or DIO were prepared by dissolving appropriate amount of
particles in RPMI-1640 with 1% L-glutamine and 10% LPDS. The concentration of iron
was determined by ICP-MS. The stock solutions were diluted with media to give series of
three solutions with decreasing iron concentration. All solutions were prepared by weight
and iron concentrations were calculated based on the concentration of the stock solution and
appropriate dilution factors. The resultant media solutions of SDIO or DIO were incubated
in 37°C water bath for 20 min before use. After removal of maintenance media, the SDIO or
DIO medium solutions were introduced to the cells and incubated at 37 °C in 5% CO2
atmosphere for 2 h. After removal of the media, cells were washed with 1X PBS (37 °C) (3
× 2 mL for each dish, ~ 2 min for each washing). Deionized water was added in dishes (1.2
mL for each dish), and the freeze-thaw (30/20 min) method was repeated twice to lyse cells.
The cell lysates were put into 1.5 mL conical tubes and lyophilized. Deionized water was
added to the residue (0.3 mL each) to generate solutions for relaxation time measurement.
2.4.3. Specificity of Uptake—To verify that cellular uptake was receptor-specific,
competition experiments were conducted and characterized by relaxation times. The
P388D1 cells were incubated with SDIO ([Fe] = 5.0 × 10−5 M) in the presence of competing
dextran sulfate or non-competing dextran as control in 0, 0.02, 0.1, 0.4, 1, and 10-fold
excess concentrations. Cells were incubated at 37 °C in a 5% CO2 atmosphere for 2 h and
then prepared for relaxation time measurement as described previously.
2.4.4. Cytotoxicity—Cytotoxicity of SDIO was evaluated with P388D1 cells using the
C12 - Resazurin viability assays. P388D1 cells in RPMI-1640 were plated in 96-well dishes
at a concentration of 1.1 × 104 cells per well. This places the cells at a density for linear
growth rate which is optimal for the assay. After overnight incubation in 5% CO2
atmosphere at 37°C, the existing RPMI-1640 was replaced with fresh media containing
varying amounts of SDIO. Cells were incubated with SDIO for either 4 or 24 h. The media
were removed and cells were washed with 1X PBS three times, then media containing C12 -
Resazurin (5 µM) was added. After incubation for 15 minutes for reduction of the
compound, fluorescence was measured using a Safire2 monochromator microplate reader
(Tecan Austria G.M.B.H., Austria) with excitation of 563 nm and an emission of 587 nm.
Samples were performed in triplicate to provide statistical significance.
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2.5. Animal studies
2.5.1. Animal model—All animal experiments were performed under protocols approved
by the Animal Care and Use Committee of the University of California, Davis and the
California Institute of Technology. Apo E−/− mice (12 weeks old, Jax West Laboratories,
West Sacramento, CA) were used for the experiments. Either the right or left carotid artery
of each mouse was ligated two weeks before imaging. Subsequent to ligation, mice were
placed on a high fat diet (TD.88137, Harlan Laboratories Inc., Madison, WI). To perform
the ligation a medial incision was made between the mandible and clavicle, exposing the
glands and vessels of the neck. The carotid artery was singled out from the surrounding
tissue, with much attention given to protecting and excluding the parallel-running vagus
nerve. A 6/0 silk suture was threaded under the dorsal side of the carotid artery and was tied
off to cause injury to the site. The procedure was concluded with five to six discontinuous
4/0 ethilon sutures to reconnect the skin of the original ventral incision. The mice were
monitored twice a day for approximately four days to check for irritation and to administer
analgesics when appropriate.
2.5.2. In vivo MRI—All images were acquired on a 7T (Bruker Biospec) small animal
magnet using a home-built birdcage coil. For all time points, the animal was anesthetized
with an 1.5% isofluorane:air mixture, kept at 35–37°C with warm air flowing through the
bore and the respiration was monitored (MP150, Biopac, Goleta, CA). After localizing the
ROI around the neck using a RARE spin echo sequence (TR/TE = 4000/22ms, matrix size =
128×128, FOV = 35.35×35.35mm2, slice thickness = 0.754mm), the common carotid
arteries were located with a time-of-flight angiography sequence with venous saturation
(FL2D_ANGIO method, Paravision 4.0: TR/TE = 13.7/3.5ms, matrix size = 150×100; zero-
filled to 256×100, FOV = 30×20mm2, slice thickness = 0.754mm). A gradient echo
sequence was then utilized to visualize the uptake of SDIO/DIO particles (TR/
TE=1000/5ms, F.A. = 35°, matrix size = 200×200; zero-filled to 256×200, FOV =
35.35×35.35mm2, slice thickness = 0.754mm) at the region of the common carotid arteries.
A set of pre-injection images was acquired one day prior to injection. For particle injection,
30 mg/kg Fe content of SDIO (n = 3) or DIO (n = 2) particles dissolved in saline were
injected via the tail vein. The imaging protocol was then repeated at 4 hours and 24 hours
post injection.
2.5.3. MR images analysis—To analyze the acquired images, all gradient echo images
were first reconstructed such that the intensity scaling and offset of all images for each
mouse were equivalent. To compare particle uptake between timepoints and subjects, we
define a contrast ratio (CR) metric as:
Where Iligated is the mean intensity of the region of interest (ROI) drawn around the ligated
carotid artery, Icontrol is the mean intensity of the ROI drawn around the contra-lateral
carotid. Ibrain is the mean intensity of the ROI drawn in the spinal cord at the same image
slice as the other ROIs and i is either 4 or 24 hours post-injection timepoints. ROIs were
drawn manually at slice levels approximately located at the common carotid arteries. These
were matched between timepoints. Angiography images were used to guide ROI delineation
around the carotid arteries. Because previous reports noted that the carotid vessels along
with the wall are ~1 mm in diameter,[22] all arterial ROIs had diameters of 1.5 mm. CR for
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SDIO injected mice and DIO injected mice were compared using a two-sided t-test in
Microsoft Excel.
3. Results and Discussion
3.1. Synthesis of SDIO
The DIO were synthesized according to our previously reported procedure.[20] The
sulfation of polysaccharides has been reported via both heterogeneous and homogeneous
synthesis pathways. Heterogeneous sulfation reactions with chlorosulfonic acid are subject
to major drawbacks such as multiple and non-reproducible side reactions, presence of
hazardous and non-reproducible sulfation rates and patterns, and backbone degradation.
Homogeneous sulfation of dextran with nitrogen base complexes of sulfur trioxide in aprotic
solvents are the preferred method; however, homogeneous reactions are still accompanied
by some non-reproducible side reactions such as cleavage of labile functional groups and
backbone degradation.[23] Our first effort to sulfate DIO followed literature methods, which
performed sulfation of dextran with sulfur trioxide pyridine complex in dry formamide at
room temperature.[24] However, the resultant particles showed 2 size peaks with an average
hydrodynamic diameter of 122 ± 97 nm. The sulfation reaction was reassessed under
different synthetic conditions including varying temperatures, using sulfur trioxide DMF
complex as sulfating agent, or using DMF as reaction solvent, yielding similar results. This
indicates that although sulfation of dextran with nitrogen base complexes of sulfur trioxide
is well-known,[23] successful translation to a dextran coat on a nanoparticle is not trivial.
The larger-sized peak may have been due to the depolymerization of dextran followed by
aggregation of incompletely coated iron oxide nanoparticles.
Sulfur trioxide pyridine complex is made by dripping chlorine sulfate acid into dry pyridine
at −15 °C.[24] However, the presence of pyridine may only partially limit the highly acidic
character of chlorosulfonic acid, which is known to be responsible for multiple, undesirable,
and non-reproducible side reactions such as cleavage of acid labile functional groups and
partial depolymerization.[25] We therefore introduced an acid scavenger of a neutral nature,
2-methyl-2-butene (2M2B), into the reaction before the addition of sulfation agent,
hypothesizing that this would clear the free acid produced in the system in a timely fashion
and lead to a more efficient reaction, with diminished side reactions in the sulfation of
dextran coat on IO NPs (Scheme 1).[25–26] The purified, sulfated DIO were turned out to
be mono-dispersed nanoparticles.
3.2. Characterization of SDIO
3.2.1. SDIO formation verification—Successful sulfation was verified by infrared
spectroscopy and elemental analysis of the purified particles. Compared to the infrared
spectrum of DIO, new absorptions of S=O groups at 1234 cm−1 (asymmetrical stretch),
1011 cm−1 (symmetrical stretch), and 826 cm−1 (symmetrical C-O-S stretch) were observed,
while the absorptions at 3426 cm−1 (O-H stretch) and 1026 cm−1 (C-O stretch) were
decreased in the infrared spectrum of SDIO.[24] The emergence of sulfur (9.74%) and
decrease of iron content (from 17.7% in DIO to 11.34% in SDIO) in SDIO further verified
successful sulfation of DIO. The results from elemental analysis of sulfur content also
showed that a two-hour reaction time was sufficient for the sulfation of DIO; longer reaction
time did not appear to increase sulfation.
3.2.2. SDIO size, relaxivity and surface charge—SDIO has an average core size of
7–8 nm (Figure 1a) and an average hydrodynamic diameter of 62.4 nm (Figure 1b), an r1
relaxivity of 18.1 mM−1s−1, and an r2 relaxivity of 95.8 mM−1s−1 (37 °C, 1.4 T) in pH 7.0
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deionized water. The r2 to r1 ratio was 5.4, indicating that SDIO could be used, preferably,
as a T2-weighted MRI contrast agent.
The measured zeta potential (ζ) values were − 14.90 mV and − 40.05 mV for DIO and
SDIO, respectively. Typically the ζ value reflects the electric charge on the particle surface
and indicates the physical stability of dispersions and emulsions in a colloidal system.[27]
Double layers with high ζ values would create powerful electrostatic repulsion and,
consequently, prevent aggregation resulting from collisions caused by Brownian motion. In
comparison with DIO, the ζ value of SDIO decreased by 25.15 mV, indicating a more stable
dispersion and emulsification of SDIO in water. In practice, we found SDIO to be very
stable, with a long shelf life in aqueous solution. We have not observed any properties to
change (e.g. aggregation, size, and magnetic property) after benchtop storage for over a year
at room temperature.
Dextran in DIO is coated on the surface of iron oxide core. Due to decreased access for
hydroxyl groups that lay deeper in the polymer layer, we estimate that the degree of
sulfation of outer polymer layer is greater than that of the inner polymer layer. This should
be ideal because the maximum sulfation of surface dextran can greatly increase the targeting
ability of the nanoparticles to macrophages with less charge repulsion at the inner polymer
layers that can affect size and MRI properties. Particle size was somewhat larger in
comparison with that of non-sulfated DIO. This is likely due to the repulsion of negatively
charged sulfate groups on the surface of SDIO. The r1 and r2 relaxivity values of SDIO were
similar to those of DIO. This is not unexpected as the size of the iron oxide cores was
similar for DIO and SDIO. Reproducibility of our method was validated by repeating the
same reaction; running the reaction with a different scale of DIO; and using sulfur trioxide
DMF complex as sulfation agent instead of sulfur trioxide pyridine complex. All of these
reactions gave similar products, indicating that our sulfation procedure is reproducible and
robust.
3.3. Cell experiments
3.3.1. SDIO targeting to macrophages P388D1—We selected SR-A as the target for
our particles because it is highly expressed on activated macrophages in atheromas. SR-A
recognizes and binds a number of polyanionic molecules, such as oxidized LDL, that
contribute to the involvement of macrophages in the formation of plaques.[28] For example,
experiments conducted on Apo E knockout (Apo E−/−) mice demonstrated that knocking out
SR-A resulted in a significant decrease in atherosclerotic plaque size.[29] To demonstrate
targeting of SDIO to macrophages, we performed in vitro studies using P388D1 murine
macrophage cells. Uptake of DIO was also performed as a control for comparison; the
properties of the DIO particles were similar to those of the commercially available MRI CA
Sinerem (Table 1).[30]
The T2 values of the lysates of macrophages incubated with increasing concentrations of
SDIO or DIO for 2 hours are shown in Figure 2. In comparison with DIO, the mean T2
values were significantly lower for cell lysates incubated with SDIO at all concentrations. In
comparison with the lysates of blank macrophages, SDIO at 5.0 × 10−5 M Fe significantly
decreased T2 by 70% (p value = 0.002), compared to a 20% T2 decrease (p value = 0.03) for
the same iron concentration of DIO, indicating that there was limited uptake of DIO
compared to SDIO under the same conditions. This result was as expected because DIO is
not a ligand of SR-A so it is not recognized by the receptor. Our results demonstrate that
sulfation of DIO facilitates SR-A targeting, and greatly improves accumulation of the
particles in macrophages over the non-targeted, dextran coated particles.
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3.3.2. Receptor-mediated uptake of SDIO by macrophages P388D1—Specificity
for the cellular uptake of SDIO was confirmed by competition studies in which cells were
incubated with a fixed concentration of SDIO and increasing excess of unlabeled dextran
sulfate (ligand of SR-A) or dextran (not a ligand of SR-A). If uptake of the agents was
receptor-mediated, the excess unlabeled ligand should compete for binding to the receptors.
Nonspecific uptake is strictly concentration-dependent and would not be affected by
additional ligands in the solution.[16, 31] Receptor-mediated uptake of SDIO was confirmed
by the results seen in Figure 3: increasing amounts of competitor, from 0.02 to 10-fold
excess, strongly reduce uptake, while increasing amounts of excess dextran had little
influence on the uptake, indicating that the uptake of SDIO by SR-A is a receptor-mediated
process. To exclude the possibility that the reduced uptake of SDIO in the presence of
dextran sulfate is caused by toxicity or any other influence of dextran sulfate on the cells
themselves, dextran sulfate alone, at the same concentrations, was applied to P388D1 cells
in culture and the cell viability was evaluated by the C12 - Resazurin viability assay.[32] The
average cell viability was above 96% after either 4 h or 24 h incubation of cells with the
concentration of dextran sulfate varying from 0.04 to 10 × 10−3 M, indicating that the
dextran sulfate is not toxic to mammalian cells (Supplementary Figure 1).
3.3.3. Cytotoxicity of SDIO to mammalian cells—As a preliminary assessment of
SDIO's toxicity to cells, SDIO were applied to P388D1 cells in culture and the cell viability
was evaluated by the C12 - Resazurin viability assay.[32] Untreated cells served as negative
control. The average cell viability is above 96% or 94% after 4 h or 24 h incubation with the
particles varying from 0.02 to 5 × 10−3 M iron, respectively (Figure 4). The result showed
that SDIO at concentrations relevant for biological imaging do not have observable toxicity
to mammalian cells. This is similar to the results for most of the in vitro cytotoxicity studies
on iron oxide nanoparticles reported in the literature.[33–36]
A major concern that limits the use of nanomaterials in clinic is the potential toxicity. The
iron oxide nanoparticles have been used in the clinic due to their biocompatiblity. After
injection the IO NPs are taken up in the liver and spleen where they are metabolized and
broken down slowly to release free iron ions. The released iron ions are added to the body’s
iron stores and eventually incorporated by erythrocytes as hemoglobin.[37] Free iron ions
could potentially be cytotoxic because of the catalytic function of iron in the production of
reactive oxygen species (ROS), which in turn can cause lipid peroxidation, protein
oxidation, and DNA damage. However, the body has the ability to process these released
iron ions as indicated by iron’s large median lethal dose (LD50) of 450 mg/kg for oral
ingestion in the rat model.[10, 14] In fact, iron oxide nanoparticle MRI contrast agents have
maintained an excellent safety record since they were approved for clinical use.[37–38]
3.4. Animal studies
The Apo E−/− mouse is a widely accepted model for atherosclerosis. In practice, we found
that ligation of carotid arteries was an effective method to generate macrophage laden
plaques.[18] The carotid artery is relatively superficial and more amenable to surgical
procedures than the coronary artery. Therefore, to evaluate the preliminary in vivo
capabilities of SDIO we utilized a carotid ligation model. A single carotid artery in the Apo
E−/− mouse (n= 5) was ligated two weeks prior to the imaging study to induce
atherosclerotic plaques. A T2*-weighted MRI with gradient echo sequence was utilized to
visualize the uptake of SDIO and DIO particles. Image slices from a representative mouse,
matched at the same slice level of the mouse common carotid arteries over a 24-h time
course are shown in Figure 5a.
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Because SDIO is a negative contrast agent, regions taking up SDIO produce a T2*
susceptibility effect, appearing darker than areas without SDIO. The MR images displayed a
sizeable decrease in the signal of the ligated carotid artery at 4 and 24 h compared to the pre-
injection image. The result parallels that from the in vitro particle incubation time study that
showed that T2 values of the lysates of macrophages incubated with SDIO decreased
substantially after a 4h incubation time with little subsequent change (Supplementary Figure
2). No discernable signal decrease was seen on the control carotid artery. This suggests
preferential uptake of the SDIO particles at the sites of atherosclerotic plaque. Image slices
from a representative mouse injected with DIO particles is shown in Figure 5b. Compared to
SDIO injected animals, less signal intensity decrease was seen over time for the DIO
injected subjects. Visualization of the volume regions above and below each slice depicted
in Figure 5, shown in Supplementary Videos 1–6, confirmed that the signal decreases
observed were due to localization of contrast agent, and not in homogenities in endogenous
signal between slices.
To compare the relative uptake between SDIO and DIO particles in a more quantitative
manner, we define a contrast ratio (CR) metric to measure the magnitude of signal decrease
at the arterial site. As seen in Figure 6, the CR of SDIO injected mice were significantly
higher than those of the DIO injected mice by 4 h post injection (p value = 0.03). This
suggests that at the same injected iron dose, SDIO accumulated preferentially compared to
DIO particles at the site of atherosclerotic plaque. It should be noted that the ROIs
delineated included the signal contribution of particles in the blood. We normalize for this
effect by comparing between the left and right carotids, which factors out the signal
contribution due to blood borne particles.
Iron oxide nanoparticle-enhanced MRI has been reported to be able to identify
atherosclerotic plaques in both in vivo animal and human studies.[14] However, the non-
specific contrast agents are taken up by activated macrophages in vulnerable plaques via
phagocytosis, pinocytosis or fluid-phase transport, which are inefficient processes.[15] As a
result, direct visualization of atherosclerotic plaques often required relatively large amounts
of nanoparticles.[14, 39] A tissue-specific contrast agent would allow for an improved
identification of these lesions.[38, 40] Active targeting of nanoparticles can be achieved by
decorating them with a ligand against a known marker associated with lesions. Our in vivo
MRI images revealed that at 4 h post-injection, targeted SDIO provided a 4-fold increase in
the contrast ratio compared to non-targeted DIO. The contrast ratio metric was used to
account for differences in anatomy and physiology between subjects. Comparing the signal
decrease between the ligated and control artery region normalizes the metric and allows
cross comparisons over timepoints and between subjects. It should be noted that the ROIs
delineated included the signal contribution of particles in the blood. We normalize for this
effect by comparing between the left and right carotids, which factors out the signal
contribution due to blood borne particles. Comparison between the CR of SDIO versus DIO
injected mice (Figure 6) suggests a time-dependence for optimal SDIO uptake. This is likely
to be a function of the degree of vulnerability of the plaque at the local site as well as the
general pharmacokinetics of the particles. Future studies will aim to correlate this with ex-
vivo assays to further understand the mechanism of particle accumulation.
We have previously shown the SR-A is a viable target for labeling macrophages and
atherosclerotic plaques.[16–17] Recently, micelles containing gadolinium chelates and
antibodies against SR-A have been synthesized and applied to MRI of aortic plaques in Apo
E−/− mice. In vivo MRI revealed that at 24 h postinjection, targeted micelles provided a 79%
increase in signal intensity of atherosclerotic aortas compared with 34% using non-targeted
micelles, and no enhancement occurred using Gd-DTPA. Uptake of the micelles was shown,
through competition experiments, to be a receptor-mediated process.[41] However, the
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potential immunogenicity of antibodies and cost to generate them in a quantity may limit the
use of immunomicelles clinically.[10] Small molecules or polymers are alternatives to
antibodies.[42] SR-A recognizes a wide range of ligands that are polyanionic, though not all
polyanionic molecules. Our results show that sulfation of dextran coated IO NPs greatly
increased the negative charges on the particle surface (high negative ζ value); this allowed
the particles to be recognized by SR-A and accumulate at the injured carotid artery in vivo.
Competition studies support that the particles were taken up by a receptor-mediated uptake
and not merely due to nonspecific electrostatic association.
Macrophages and macrophage scavenger receptors play a key role in the pathogenesis of
atherosclerosis. Macrophages are present through all stages of atherosclerosis development,
from the initiation of plaques through the formation of complex plaques containing foam
cells, necrotic debris, and thrombi, and have been specifically associated with plaque
stability—high densities of macrophages correlate with vulnerability to rupture.[5, 13] Our
results show that SDIO can be recognized and specifically taken up by macrophages via
scavenger receptor. Their specific accumulation at the injured carotid, but not the control
carotid, suggests the potential to use SDIO with MRI to detect and distinguish inflamed
atherosclerotic plaques.
4. Conclusion
The use of MRI is a well-established means for injury and disease diagnosis on the anatomic
scale. Current advances in targeted contrast agents allow researchers to gather in vivo
anatomic and molecular information simultaneously. IO NPs modified to target various
moieties in atherosclerotic plaques have demonstrated their utility as an important tool for
enhancing magnetic resonance detection of atherosclerosis at the anatomical, cellular and
molecular levels.[43] However, to date, reports of targeted MRI of macrophages, a key
component in the formation and development of vulnerable plaques, are relatively rare. In
this paper, we sulfated dextran coated IO NPs and therefore targeted the nanoparticles to
scavenger receptors on macrophages. SDIO has a high r2 value of 95.84 mM−1s−1 and an r2/
r1 ratio of 5.3 (37 °C, 1.4 T), therefore acts as an efficient T2-weighted MRI contrast agent.
We demonstrate that SDIO nanoparticles are specifically and avidly taken up by
macrophages via a receptor-mediated process that labels macrophages much more
efficiently than nonsulfated analogues, and produces distinct contrast in both in vitro and in
vivo T2*-weighted MRI images. High macrophage density has been associated with
atherosclerotic plaques vulnerable to rupture. Thus, the specific targeting of macrophages
with the MR nanoparticle imaging agent SDIO demonstrates the potential for SDIO to
facilitate detection and diagnosis plaque stability with in vivo MRI.
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Fig. 1.
(a) TEM, and (b) DLS of dextran sulfate coated iron oxide nanoparticles (SDIO).
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Fig. 2.
Mean T2 values of cell lysates incubated for 2 h with SDIO ( ) or DIO ( ) of different iron
concentrations.
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Fig. 3.
Competitive uptake of SDIO ([Fe] = 5.0 × 10−5 M) and dextran sulfate ( ), or dextran ( )
by P388D1 cells.
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Fig. 4.
Cell viability of P388D1 after 4- ( ), or 24-h ( ) incubation with different concentrations of
SDIO.
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Fig. 5.
Signal change in MRI over time after SDIO (a) or DIO (b) injection. The ligated carotid
artery is denoted by the yellow arrow and the control carotid artery is denoted by the red
arrow. Circles indicate the ROI measures used to derive the contrast ratio (CR) metric. To
facilitate comparison, the magnified images in carotid areas were first rotated in plane so all
time points in the orientation. They were then zero-filled by a factor of 2 and then smoothed
with a 2×2 Gaussian filter. (Scale bar = 10 mm, both scale bar and intensity bar apply to the
whole animal images only. L = left, R = right, green box shows magnification area, white
arrow denotes the trachea)
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Fig. 6.
Contrast Ratio between SDIO and DIO particle accumulation in vivo.
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Scheme 1.
Sulfation of dextran coated iron oxide nanoparticles.
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